Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02312557 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute.

Active
Registry status
Phase 2
Development phase
58
Enrollment target
1
Study location

NCT02312557 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 58 participants, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02312557, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Recurrent Prostate Carcinoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well pembrolizumab works in treating patients with prostate cancer that has spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels despite previous treatment with enzalutamide. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.

Conditions Studied

Castration-Resistant Prostate Carcinoma Recurrent Prostate Carcinoma Hormone-Resistant Prostate Cancer PSA Progression Stage IV Prostate Adenocarcinoma Cancer AJCC v8

Interventions

  • BIOLOGICAL Pembrolizumab
  • OTHER Laboratory Biomarker Analysis
  • DRUG Enzalutamide

Study Locations (1)

Oregon

  • OHSU Knight Cancer Institute - Portland

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2014-11-18
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

OHSU Knight Cancer Institute

211 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02312557

The ClinicalTrials.gov registry entry for NCT02312557 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (25% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT02312557 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT02312557 about?

NCT02312557 is a clinical study titled "Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide". This phase II trial studies how well pembrolizumab works in treating patients with prostate cancer that has spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels despite previous treatment with enzalutamide. Monoclonal ant...

What is the current status of trial NCT02312557?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2014-11-18. Estimated completion is 2026-06-30.

What conditions does trial NCT02312557 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Stage IV Prostate Adenocarcinoma Cancer AJCC v8.

What interventions are being tested in trial NCT02312557?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Enzalutamide (DRUG).

Who is sponsoring clinical trial NCT02312557?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02312557 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Castration-Resistant Prostate Carcinoma

All registered trials for this condition

Recurrent Prostate Carcinoma

All registered trials for this condition

Oregon

All trials with a study site in Oregon

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.